Financials PDS Biotechnology Corporation
Equities
PDSB
US70465T1079
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.915 USD | +0.52% | -2.18% | -41.35% |
May. 15 | PDS Biotechnology Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 10 | NetScientific says PDS Biotech's Versamune meets endpoints | AN |
Valuation
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 14 | 47.64 | 230.3 | 376.3 | 154.6 | 106.4 | - | - |
Enterprise Value (EV) 1 | 14 | 47.64 | 230.3 | 376.3 | 154.6 | 106.4 | 106.4 | 106.4 |
P/E ratio | - | -2.4 x | -12.3 x | -9.23 x | -3.58 x | -2.2 x | -1.97 x | -2.56 x |
Yield | - | - | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - | - | 9.46 x |
EV / Revenue | - | - | - | - | - | - | - | 9.46 x |
EV / EBITDA | -0.67 x | -3.2 x | -10.7 x | -9.03 x | -3.6 x | -2.47 x | -1.54 x | -2.08 x |
EV / FCF | -0.77 x | - | - | -14.6 x | -4.6 x | -1.9 x | -1.64 x | -1.44 x |
FCF Yield | -129% | - | - | -6.83% | -21.8% | -52.6% | -61.1% | -69.5% |
Price to Book | - | - | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 5,281 | 22,262 | 28,438 | 28,509 | 31,108 | 36,679 | - | - |
Reference price 2 | 2.650 | 2.140 | 8.100 | 13.20 | 4.970 | 2.915 | 2.915 | 2.915 |
Announcement Date | 3/27/20 | 3/18/21 | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | 11.25 |
EBITDA 1 | -20.94 | -14.89 | -21.43 | -41.67 | -42.99 | -43.14 | -69 | -51.1 |
EBIT 1 | -21.03 | -14.9 | -21.44 | -41.67 | -43.05 | -47.08 | -54.35 | -58.12 |
Operating Margin | - | - | - | - | - | - | - | -516.59% |
Earnings before Tax (EBT) 1 | - | -14.85 | -21.43 | -42.05 | -44.35 | -46.79 | -66.6 | -55.8 |
Net income 1 | - | -14.85 | -16.92 | -40.85 | -42.94 | -48.65 | -62.51 | -58.22 |
Net margin | - | - | - | - | - | - | - | -517.48% |
EPS 2 | - | -0.8900 | -0.6600 | -1.430 | -1.390 | -1.322 | -1.482 | -1.137 |
Free Cash Flow 1 | -18.07 | - | - | -25.71 | -33.64 | -55.96 | -64.99 | -73.94 |
FCF margin | - | - | - | - | - | - | - | -657.24% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - |
Announcement Date | 3/27/20 | 3/18/21 | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | -6.321 | -8.479 | -7.093 | -7.279 | -18.82 | -9.419 | -12.69 | -10.51 | -10.39 | - | -10.31 | -10.51 | -12.16 | - | - |
EBIT 1 | -6.322 | -8.479 | -7.093 | -7.279 | -18.82 | -9.422 | -12.7 | -10.52 | -10.41 | -10.1 | -11.49 | -11.98 | -12.98 | - | - |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -6.32 | -8.474 | -7.018 | -7.424 | -19.14 | -9.66 | -12.94 | -10.85 | -10.9 | -10.6 | -11.01 | -11.58 | -13.61 | - | - |
Net income 1 | -6.32 | -8.474 | -5.819 | -7.424 | -19.14 | -9.66 | -11.53 | -10.85 | -10.9 | -10.6 | -11.56 | -13.35 | -14.07 | - | - |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.2300 | -0.3200 | -0.2000 | -0.2600 | -0.6700 | -0.3200 | -0.3700 | -0.3500 | -0.3500 | -0.3000 | -0.3280 | -0.3400 | -0.3360 | -0.3500 | -0.3700 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/31/22 | 5/11/22 | 8/8/22 | 11/14/22 | 3/28/23 | 5/15/23 | 8/14/23 | 11/14/23 | 3/27/24 | 5/15/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
Free Cash Flow 1 | -18.1 | - | - | -25.7 | -33.6 | -56 | -65 | -73.9 |
ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - | - | - |
Capex 1 | - | - | - | - | - | 0.8 | 0.8 | 0.8 |
Capex / Sales | - | - | - | - | - | - | - | 7.11% |
Announcement Date | 3/27/20 | 3/18/21 | 3/31/22 | 3/28/23 | 3/27/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.35% | 107M | |
+18.72% | 125B | |
+14.19% | 108B | |
-4.93% | 24.21B | |
+3.23% | 22.78B | |
-10.44% | 17.96B | |
-41.74% | 16.43B | |
-13.31% | 16.37B | |
+2.44% | 13.58B | |
+27.89% | 11.66B |
- Stock Market
- Equities
- PDSB Stock
- Financials PDS Biotechnology Corporation